Is MRTX or RYLD a better dividend investment in 2026?

MRTX currently yields 3.41% with a 5% 5-year dividend growth rate. RYLD yields 4.00% with 5% growth. The better choice depends on your goal: RYLD offers higher current income.

What is the dividend yield difference between MRTX and RYLD?

MRTX has a forward dividend yield of 3.41% ($2.00/share annually). RYLD yields 4.00% ($2.00/share annually). The yield gap is 0.59 percentage points.

Home › Compare › MRTX vs RYLD

MRTX vs RYLD: Dividend Comparison 2026

MRTX yields 3.41% · RYLD yields 4.00%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 RYLD wins by $3.1K in total portfolio value

INVESTMENT

TIME HORIZON10 years

MRTX

● Live price

3.41%

Share price

$58.70

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$24.9K

Annual income

$424.22

Full MRTX calculator →

RYLD

● Live price

4.00%

Share price

$50.00

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$28.0K

Annual income

$899.19

Full RYLD calculator →

Portfolio growth — MRTX vs RYLD

📍 RYLD pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	MRTX	RYLD
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, MRTX + RYLD cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

MRTX pays

RYLD pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MRTX

Annual income on $10K today (after 15% tax)

$289.61/yr

After 10yr DRIP, annual income (after tax)

$360.59/yr

RYLD

Annual income on $10K today (after 15% tax)

$340.00/yr

After 10yr DRIP, annual income (after tax)

$764.31/yr

At 15% tax rate, RYLD beats the other by $403.72/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MRTX + RYLD for your $10,000?

MRTX: 50%RYLD: 50%

100% RYLD50/50100% MRTX

Portfolio after 10yr

$26.5K

Annual income

$661.71/yr

Blended yield

2.50%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRTX right now

MRTX

Analyst Ratings

Buy

Hold

Consensus: Hold

Price Target

$102.10

+73.9% upside vs current

Range: $53.00 — $247.00

Altman Z

8.6

Piotroski

3/9

RYLD

No analyst data

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MRTX buys

RYLD buys

No recent congressional trades found for MRTX or RYLD in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricMRTXRYLD

Forward yield	3.41%	4.00% ✓
Annual dividend / share	$2.00	$2.00
Payout ratio	50%	50%
1-year div growth	0%	5% ✓
5-year div CAGR	0%	5% ✓
Portfolio after 10y	$24.9K	$28.0K ✓
Annual income after 10y	$424.22	$899.19 ✓
Total dividends collected	$3.8K	$6.4K ✓
Payment frequency	quarterly	quarterly
Sector	Stock	ETF

Year-by-year: MRTX vs RYLD ($10,000, DRIP)

Year	MRTX Portfolio	MRTX Income/yr	RYLD Portfolio	RYLD Income/yr	Gap
1← crossover	$11,041	$340.72	$11,120	$420.00	$79.00 → RYLD
2	$12,165	$351.56	$12,357	$458.31	$192.00 → RYLD
3	$13,379	$362.03	$13,721	$499.76	$342.00 → RYLD
4	$14,687	$372.10	$15,227	$544.58	$540.00 → RYLD
5	$16,097	$381.77	$16,885	$593.02	$788.00 → RYLD
6	$17,615	$391.04	$18,713	$645.34	$1.1K → RYLD
7	$19,248	$399.92	$20,724	$701.81	$1.5K → RYLD
8	$21,004	$408.41	$22,938	$762.73	$1.9K → RYLD
9	$22,891	$416.50	$25,372	$828.41	$2.5K → RYLD
10	$24,917	$424.22	$28,047	$899.19	$3.1K → RYLD

MRTX vs RYLD: Complete Analysis 2026

MRTX — Stock

Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; and Sitravatinib, an investigational spectrum-selective kinase inhibitor that is in Phase 3 clinical trial for the treatment of NSCL cancer, as well as a KRAS G12D inhibitor program, which is in preclinical development. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.

Full MRTX Calculator →

RYLD — ETF

RYLD is a dividend-paying stock. Use this calculator to estimate your future dividend income, DRIP compounding returns, and passive income potential from investing in RYLD shares.

Full RYLD Calculator →

📬

Get this MRTX vs RYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MRTX vs SCHD MRTX vs JEPI MRTX vs O MRTX vs KO MRTX vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.